Patients with locally advanced and metastatic low-tumor burden prostate cancer have similar oncologic outcomes, investigators reported at the American Urological Association’s 2023 Annual Meeting in Chicago, Illinois.
Tashikazu Tanaka, MD, of Aomori Prefectural Central Hospital in Aomori, Japan, and colleagues retrospectively studied 505 patients treated with androgen deprivation therapy alone: 186 with locally advanced (T4 or N+) prostate cancer (M0-advanced group) and 319 with metastatic low-tumor burden prostate cancer (M1-low group). Of the 505 patients, 138 (27.3%) previously had undergone local treatment (radical prostatectomy or radiation therapy). The investigators compared the groups with respect to castration-resistant prostate cancer (CRPC)-free and overall survival.
The median CRPC-free survival was 32.5 months in the M0-advanced group and 40.7 months in the M1-low group, Dr Tanaka reported in a poster presentation. The median overall survival was 140 months in the M0-advanced group and 132 months in the M1-low group. None of these between-group differences was statistically significant.
Multivariable Cox regression analysis revealed that a Gleason score of 9-10, T4 or N1 status, and no local intervention were significantly associated with poor prognosis.
Tanaka T, Hatakeyama S, Tabata R, et al. Oncological outcomes in the metastatic low tumor-burden prostate cancer are not significantly different from the locally advanced (T4 or N1) prostate cancer. Presented at: AUA 2023, Chicago, Illinois, April 28-May 1. Abstract MP29-18.